肠道菌群及代谢物与肝硬化食管胃静脉曲张的关联研究

谭 雪琪1, 覃敏 珍*2, 姚 敦卫2
1、右江民族医学院
2、百色市人民医院

摘要


肝硬化是由多种不同病因导致的终末期肝脏病变，常伴多种并发症的发生。近年来许多研究发现，肠道菌群在肝硬化及其并发症的发生发展中起着关键作用，但目前关于肠道菌群如何影响肝硬化食管胃静脉曲张（esophagogastric variceal，EGV）的具体机制仍不完全清晰。本文将详细综述肠道菌群组成变化、关键代谢物的调控机制及其在肝硬化食管胃静脉曲张发生发展中的作用。

关键词


肝硬化；食管胃静脉曲张；肠道菌群；代谢物

全文:

PDF


参考


[1]Shu W, Shanjian C, Jinpiao L, et al. Gut microbiota dysbiosis in patients with hepatitis B virus-related cirrhosis.[J]. Annals of hepatology, 2022,27(2):100676.DOI:10.1016/j.aohep.2022.100676.

[2]Lau H C, Zhang X, Yu J. Gut microbiome in metabolic dysfunction-associated steatotic liver disease and associated hepatocellular carcinoma.

[3]Yang X, Lv F, Wang R, et al. Potential role of intestinal microflora in disease progression among patients with different stages of Hepatitis B.[J]. Gut pathogens, 2020,12:50.DOI:10.1186/s13099-020-00391-4.

[4]任海霞，李淑霞，郭永泽，等.内镜联合康复新液治疗对肝硬化食管胃底静脉曲张患者口腔和肠道菌群的影响[J].现代中西医结合杂志，2023，32（17）：2393-2397.

[5]任海霞，平付敏，牛淑利，等.肝硬化食管胃底静脉曲张患者口腔和肠道菌群变化[J].河北医药，2023，45（09）：1335-1339.

[6]Yokoyama K, Tsuchiya N, Yamauchi R, et al. Exploratory Research on the Relationship between Human Gut Microbiota and Portal Hypertension.[J]. Internal medicine (Tokyo, Japan), 2020,59(17):2089-2094.DOI:10.2169/internalmedicine.4628-20.

[7]刘妹妹，林婷，王军，等.肠道微生物代谢物在肝硬化中的作用[J].中国微生态学杂志，2023，35（07）：847-851.

[8]邓永东，邢乐康，张红.乙型肝炎肝硬化合并食管胃底静脉曲张患者肠道屏障功能变化情况[J].国际检验医学杂志，2020，41（16）：1966-1969.

[9]Zhao T, Su L, Ma C, et al. IGF-1 decreases portal vein endotoxin via regulating intestinal tight junctions and plays a role in attenuating portal hypertension of cirrhotic rats.[J]. BMC gastroenterology, 2015,15:77.DOI:10.1186/s12876-015-0311-5.

[10]Wu Z, Zhou H, Liu D, et al. Alterations in the gut microbiota and the efficacy of adjuvant probiotic therapy in liver cirrhosis.[J]. Frontiers in cellular and infection microbiology, 2023,13:1218552.DOI:10.3389/fcimb.2023.1218552.

[11]Juanola O, Ferrusquía-Acosta J, García-Villalba R, et al. Circulating levels of butyrate are inversely related to portal hypertension, endotoxemia, and systemic inflammation in patients with cirrhosis.[J]. FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2019,33(10):11595-11605.DOI:10.1096/fj.201901327R.

[12]Zhang T, Li J, Liu C, et al. Butyrate ameliorates alcoholic fatty liver disease via reducing endotoxemia and inhibiting liver gasdermin D-mediated pyroptosis.[J]. Annals of translational medicine, 2021,9(10):873.DOI:10.21037/atm-21-2158.

[13]Nie G, Zhang H, Xie D, et al. Liver cirrhosis and complications from the perspective of dysbiosis.[J]. Frontiers in medicine, 2023,10:1320015.DOI:10.3389/fmed.2023.1320015.

[14]Fukui H. Leaky Gut and Gut-Liver Axis in Liver Cirrhosis: Clinical Studies Update.[J]. Gut and liver, 2021,15(5):666-676.DOI:10.5009/gnl20032.

[15]Iwakiri Y, Trebicka J. Portal hypertension in cirrhosis: Pathophysiological mechanisms and therapy.[J]. JHEP reports : innovation in hepatology, 2021,3(4):100316.DOI:10.1016/j.jhepr.2021.100316.

[16]Hendrikx T, Schnabl B. Indoles: metabolites produced by intestinal bacteria capable of controlling liver disease manifestation.[J]. Journal of internal medicine, 2019,286(1):32-40.DOI:10.1111/joim.12892.

[17]Baffy G. Potential mechanisms linking gut microbiota and portal hypertension.[J]. Liver international : official journal of the International Association for the Study of the Liver, 2019,39(4):598-609.DOI:10.1111/liv.13986.

[18]Li O, Xu H, Kim D, et al. Roles of Human Gut Microbiota in Liver Cirrhosis Risk: A Two-Sample Mendelian Randomization Study.[J]. The Journal of nutrition, 2024,154(1):143-151.DOI:10.1016/j.tjnut.2023.11.011.

[19]Shakhpazyan N K, Mikhaleva L M, Bedzhanyan A L, et al. Exploring the Role of the Gut Microbiota in Modulating Colorectal Cancer Immunity.


Refbacks

  • 当前没有refback。